Published real world evidence demonstrates KidneyIntelX™ improved clinical decisions and outcomes in high-risk patients with early-stage diabetic kidney disease
Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared ...
